Aptar Pharma’s Connected Devices Portfolio
Photo: Courtesy of Aptar Pharma
Aptar Pharma, a leading global solution provider of innovative drug delivery systems, will once again attend CPhI Worldwide. At booth 42F10, Aptar Pharma will highlight their wide product portfolio and their latest innovations addressing important healthcare technology megatrends.
A dedicated innovation corner with a special connectivity hub will center on the growing field of connected healthcare solutions. Studies show that 60% of patients fail to comply with their daily medication regimen. Aptar Pharma strongly believes that patient behavior can be changed through connected, intuitive and user-friendly devices - significantly increasing dose adherence and improving patient health outcomes.
Sai Shankar, Director Business Development – Connected Devices, will present the findings of a recent Aptar Pharma study on its integrated connected pMDI devices, in his briefing “Driving Better Patient Outcomes with Connectivity” on Tuesday, October 24 at 15h50, at the Innopack Zone G1A13. He will also underline how Aptar Pharma’s connected health devices portfolio is focused on supporting customers and patients to effectively treat diseases such as Asthma and COPD.
Visit the Aptar Pharma booth and learn more about this and other megatrends affecting drug delivery systems, and see how Aptar Pharma continues to break new ground in innovative healthcare technology solutions.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit www.aptar.com/pharma
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.